MRG-001 as an Immunoregulatory and Regenerative Therapy for ARDS Patients

Conditions: Acute Respiratory Distress Syndrome; Respiratory Failure; Respiratory Distress Syndrome; Respiratory Tract Diseases; Cytokine Storm Interventions: Drug: MRG-001 (Low-dose); Drug: MRG-001 (High-dose); Other: Placebo Sponsors: MedRegen LLC; Vanderbilt University Medical Center Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials